Is Pfizer Stock a Buy Now?

Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and its shares are down by 41% year to date. These two facts aren't unrelated. Pfizer generated record-breaking sales in 2021 and 2022 thanks to its coronavirus portfolio, which has lost momentum since the COVID-19 pandemic has largely receded.

Even so, investors could be underestimating Pfizer's potential. Let's find out why the healthcare giant is still worth investing in, especially at current levels.

Source Fool.com

Pfizer Inc. Aktie

Pfizer Inc. muss heute leichte Verluste wegstecken. Die Aktie notiert im Vergleich zu gestern um -0,81 % tiefer.
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 28.19 € bedeuten.

Like: 0

PFE

Teilen